Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Feb;178(2):e129-e131.
doi: 10.1111/bjd.15935. Epub 2017 Dec 18.

Olmutinib-induced palmoplantar keratoderma

K L Chen  1   2 , Y T Cho  1 , C W Yang  1 , Y S Sheen  1 , C W Liang  3 , M E Lacouture  4 , C Y Chu  1
Affiliations
Case Reports

Olmutinib-induced palmoplantar keratoderma

K L Chen et al. Br J Dermatol. 2018 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Dr. ME Lacouture is a Consultant for Boehringer Ingelheim International GmbH. Dr. C.Y. Chu received honoraria from Boehringer Ingelheim International GmbH for being a consultant and a speaker and from Novartis for being a consultant. The other authors had no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Patient 1. (a) About one month after the initiation of olmutinib therapy, brownish asymptomatic dispersed hyperkeratotic patches and plaques developed on the bilateral soles of the feet and shins. (b) The lesions resolved spontaneously at 1 month after discontinuation of olmutinib. (c) The pathology study showed acanthosis, hyperkeratosis and papillary dermal elongation with minimal dermal inflammation (hematoxylin and eosin stain, 100X). (d) The immunohistochemistry study showed Ki-67 positive cells confined to the basal and suprabasal layers (Ki-67 stain, 100X). Patient 2. (e) Asymptomatic, focal hyperkeratotic plaques mainly on the pressure points of the soles and (f) tips of the toes and fingers, but sparing the nails.
See this image and copyright information in PMC

References

    1. Kim ES. Olmutinib: First Global Approval. Drugs. 2016;76:1153–1157. - PubMed
    1. Patel S, Zirwas M, English JC., 3rd Acquired palmoplantar keratoderma. Am J Clin Dermatol. 2007;8:1–11. - PubMed
    1. Chen KL, Lin CC, Cho YT, et al. Comparison of skin toxic effects associated with Gefitinib, erlotinib, or afatinib treatment for non-small cell lung cancer. JAMA Dermatol. 2016;152:340–342. - PubMed
    1. Degen A, Alter M, Schenck F, et al. The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol Ges. 2010;8:652–661. - PubMed
    1. Pohler E, Mamai O, Hirst J, et al. Haploinsufficiency for AAGAB causes clinically heterogeneous forms of punctate palmoplantar keratoderma. Nat Genet. 2012;44:1272–1276. - PMC - PubMed